Revolutionizing Thyroid Nodule Surgery: The Impact of Hemi-Thyroidectomy Coupled with Intra-Operative Biopsy

Ahmed Helmy Mohamed Mortagy[1], Osama Hassan Gharib[1], Morsy Mohamed Morsy[1], Ola A. Harb[2], Ahmed Mohamed Yehia[1]

1 General Surgery Department, Faculty of Medicine - Zagazig University, Egypt

2 Pathology Department, Faculty of Medicine - Zagazig University, Egypt

Corresponding author: Ahmed Helmy Mohamed Mortagy

E-mail: ahmedhelmyrouq@gmail.com

Conflict of interest: None declared.

Funding: No funding sources

Abstract

Solitary thyroid nodules (STNs) are common clinical findings, and their management often poses a diagnostic and therapeutic challenge. Hemi-thyroidectomy, combined with intra-operative frozen section biopsy (IOFS), has emerged as a reliable technique for managing STNs. This review examines the efficacy, safety, and diagnostic accuracy of this approach. By integrating IOFS into the surgical workflow, surgeons can achieve real-time pathological assessment, enabling tailored treatment decisions during the initial surgical procedure. The review highlights the role of IOFS in differentiating benign from malignant nodules, reducing the need for subsequent surgeries, and minimizing complications associated with overtreatment. Key factors such as sensitivity, specificity, and cost-effectiveness of IOFS are critically analyzed. Furthermore, the article explores the impact of this technique on patient outcomes, emphasizing its role in achieving optimal surgical margins and preserving thyroid function. Current evidence supports hemi-thyroidectomy with IOFS as a reliable, efficient, and patient-centered approach in the management of STNs, underscoring its value in modern thyroid surgery protocols.

Keywords: Thyroid Nodule, Hemi-Thyroidectomy

Regul Sci. ™ 2023; 9(1): 9007 - 9014

DOI: doi.org/10.18001 /TRS.9.1. 645

Introduction

A solitary thyroid nodule (STN) is a common clinical finding characterized by a distinct lump within the thyroid gland. These nodules can be detected through physical examination or imaging modalities such as ultrasonography. STNs are often benign; however, the potential for malignancy necessitates a thorough evaluation to determine their etiology and guide management [1].

The prevalence of solitary thyroid nodules increases with age, affecting up to 50% of individuals over 60 years when detected by ultrasonography. These nodules are more common in women than men, and their occurrence is often associated with iodine deficiency, radiation exposure, and certain genetic factors [2].

Clinical evaluation of an STN begins with a detailed history and physical examination. Patients may report symptoms such as a visible lump, neck discomfort, or voice changes. Risk factors for malignancy include a family history of thyroid cancer, previous radiation exposure, and rapid growth of the nodule [3].

Ultrasonography is the most sensitive imaging modality for evaluating STNs. It helps determine the size, composition, and vascularity of the nodule, which are critical for assessing the risk of malignancy. Suspicious ultrasonographic features include hypoechogenicity, irregular margins, microcalcifications, and increased vascularity [4].

Fine-needle aspiration biopsy (FNAB) is the gold standard diagnostic tool for solitary thyroid nodules. This minimally invasive procedure provides cytological evaluation, categorizing nodules into benign, malignant, or indeterminate, based on the Bethesda classification system. FNAB results guide clinical decision-making and management [5].

Thyroid function tests are essential in the evaluation of STNs. Measurements of serum thyroid-stimulating hormone (TSH) levels can indicate whether the nodule is functioning (producing thyroid hormones) or non-functioning. Hyperfunctioning nodules are usually benign, while non-functioning nodules have a higher risk of malignancy [6].

Molecular testing has emerged as an adjunct to FNAB, especially for indeterminate nodules. Genetic markers, such as BRAF and RAS mutations, can help stratify the risk of malignancy and guide treatment strategies. These advancements have significantly improved the accuracy of diagnosing STNs [7].

Management of STNs depends on their size, cytological features, and clinical presentation. Benign nodules are typically monitored with periodic ultrasonography, while malignant nodules often require surgical intervention. The extent of surgery, such as lobectomy or total thyroidectomy, is determined by the malignancy risk and other patient factors [8].

Radioactive iodine therapy may be considered for hyperfunctioning nodules or residual thyroid tissue post-surgery. This treatment helps reduce the risk of recurrence and addresses any remnant disease. It is particularly effective in cases of papillary and follicular thyroid cancers [9].

The role of levothyroxine suppression therapy in managing STNs is controversial. This treatment aims to suppress TSH levels and potentially reduce nodule size, but its efficacy and safety remain topics of debate. Guidelines recommend its use on a case-by-case basis [10].

Recent advancements in ultrasonography, including elastography and contrast-enhanced imaging, have enhanced the evaluation of STNs. These technologies provide additional information about the nodule's stiffness and vascularity, which are useful in malignancy risk assessment [11].

Epidemiological studies have highlighted the impact of environmental and dietary factors on the prevalence of STNs. Iodine supplementation programs in iodine-deficient regions have been effective in reducing the incidence of nodules and related thyroid disorders [12].

Surgical management of malignant STNs includes careful consideration of potential complications such as hypoparathyroidism and recurrent laryngeal nerve injury. Multidisciplinary approaches and advancements in surgical techniques have minimized these risks and improved patient outcomes [13].

The prognosis of patients with STNs largely depends on the histopathological diagnosis and the timeliness of treatment. Early detection and appropriate management have led to excellent outcomes, particularly for differentiated thyroid cancers such as papillary and follicular types [14].

Radiofrequency ablation (RFA) has emerged as a minimally invasive alternative for benign and selected malignant thyroid nodules. This technique uses heat to reduce nodule size and improve symptoms while preserving thyroid function [15].

The psychological impact of an STN diagnosis should not be underestimated. Patients often experience anxiety about the possibility of cancer, emphasizing the need for clear communication and supportive care throughout the diagnostic and treatment process [16].

Public health initiatives focusing on thyroid health awareness and routine screening can facilitate early detection of STNs. Educational campaigns and accessible healthcare services play crucial roles in reducing the burden of thyroid disorders [17].

The role of artificial intelligence in the evaluation of STNs is an emerging field. AI algorithms can analyze ultrasonographic images and predict malignancy with high accuracy, providing a valuable tool for clinicians in resource-limited settings [18].

Future research on solitary thyroid nodules should focus on improving diagnostic accuracy, exploring novel therapeutic options, and understanding the molecular mechanisms underlying nodule development. These efforts will contribute to personalized and effective management strategies [19], solitary thyroid nodules represent a common yet complex clinical entity requiring a multidisciplinary approach for optimal management. Advances in diagnostic techniques, molecular testing, and minimally invasive therapies have significantly enhanced patient care and outcomes [20].

Hemi-thyroidectomy with intra-operative frozen section biopsy is increasingly recognized as a reliable surgical approach in the management of solitary thyroid nodules. This technique combines partial thyroid gland removal with immediate pathological evaluation, allowing surgeons to make informed decisions regarding further surgical intervention. The ability to determine malignancy intra-operatively reduces unnecessary bilateral thyroid surgeries and minimizes postoperative complications, aligning with patient-centered care goals [21].

The solitary thyroid nodule (STN) represents a common clinical presentation, and its evaluation often necessitates a balance between diagnostic accuracy and surgical intervention. The use of hemi-thyroidectomy enables precise excision of the nodule while preserving thyroid function, which is essential for maintaining metabolic homeostasis. The frozen section biopsy augments this process by providing rapid histopathological analysis, facilitating real-time surgical decision-making [22].

Historically, the management of STN relied heavily on fine-needle aspiration cytology (FNAC). While FNAC remains a valuable diagnostic tool, its limitations in distinguishing between benign and malignant follicular neoplasms necessitate complementary approaches. Intra-operative frozen section biopsy addresses this gap by offering a definitive diagnosis during surgery, enhancing the overall reliability of the hemi-thyroidectomy procedure [23].

The integration of frozen section biopsy into surgical protocols for STN management reflects advancements in pathology and surgical technology. This approach allows for immediate feedback to the surgical team, thereby reducing the need for subsequent operations. Studies have shown that frozen section biopsy achieves high sensitivity and specificity in detecting malignancy, contributing to its acceptance as a standard practice in thyroid surgery [24].

Preservation of thyroid function is a critical consideration in the management of STN, particularly in young and middle-aged patients. Hemi-thyroidectomy, as opposed to total thyroidectomy, ensures that a portion of the gland remains intact, significantly lowering the risk of hypothyroidism. The frozen section biopsy further complements this by confirming the adequacy of surgical margins, thereby preventing overtreatment [25].

Intra-operative frozen section biopsy is particularly advantageous in cases of indeterminate thyroid nodules. These nodules, often classified as Bethesda category III or IV, pose a diagnostic challenge due to their ambiguous cytological features. By providing an immediate and accurate diagnosis, frozen section biopsy facilitates appropriate surgical planning and reduces the risk of under- or overtreatment [26].

Hemi-thyroidectomy with frozen section biopsy also demonstrates economic advantages. By preventing unnecessary total thyroidectomies, this approach reduces the overall cost of care. It also minimizes the need for lifelong thyroid hormone replacement therapy, which is often required after total thyroidectomy. These benefits make it a cost-effective strategy in the management of STN [27].

The safety profile of hemi-thyroidectomy with intra-operative frozen section biopsy is well-documented. Complications such as recurrent laryngeal nerve injury and hypoparathyroidism are significantly less frequent compared to total thyroidectomy. This improved safety profile underscores its suitability as a primary intervention for solitary thyroid nodules [28].

Patient satisfaction is another critical factor in evaluating the efficacy of surgical techniques. The minimally invasive nature of hemi-thyroidectomy, combined with the precision offered by frozen section biopsy, ensures better cosmetic outcomes and reduced recovery times. Studies consistently report higher patient satisfaction scores among individuals undergoing this combined approach [29].

The use of frozen section biopsy during hemi-thyroidectomy also enhances the multidisciplinary approach to thyroid nodule management. Surgeons, endocrinologists, and pathologists work in tandem to ensure optimal outcomes. This collaborative model not only improves diagnostic accuracy but also fosters a patient-centered approach to care [30].

Frozen section biopsy is particularly effective in identifying papillary thyroid carcinoma (PTC), the most common type of thyroid cancer. Its ability to detect characteristic nuclear features intra-operatively allows surgeons to make immediate and informed decisions about the extent of surgery required. This is especially crucial in achieving oncological control while preserving thyroid function [31].

The role of intra-operative frozen section biopsy extends beyond the immediate surgical setting. Its findings guide postoperative management, including the need for radioactive iodine therapy and long-term surveillance. This comprehensive approach ensures that patients receive tailored treatment plans based on accurate pathological diagnoses [32].

Hemi-thyroidectomy with frozen section biopsy has a particular advantage in managing microcarcinomas, which are small thyroid cancers often detected incidentally. The ability to confirm malignancy intra-operatively allows surgeons to limit the extent of surgery, thereby avoiding unnecessary morbidity associated with more extensive procedures [33].

Frozen section biopsy is not without its limitations. False negatives, though rare, can occur and may lead to incomplete surgical management. However, advancements in pathological techniques and surgeon-pathologist communication continue to improve the accuracy and reliability of this method, reinforcing its role in modern thyroid surgery [34].

The application of frozen section biopsy during hemi-thyroidectomy has also been explored in the context of rare thyroid neoplasms, such as medullary thyroid carcinoma and Hurthle cell neoplasms. While these cases are less common, the technique provides valuable insights, enabling precise surgical interventions tailored to the specific pathology [35].

The incorporation of frozen section biopsy into thyroid surgery protocols reflects broader trends in precision medicine. By offering real-time pathological evaluation, this approach aligns with the principles of personalized care, ensuring that each patient receives the most appropriate surgical and postoperative management [36].

Recent studies have highlighted the role of frozen section biopsy in reducing healthcare disparities. By providing definitive diagnoses intra-operatively, this technique minimizes delays in care for patients with limited access to advanced diagnostic facilities. This contributes to more equitable health outcomes across diverse populations [37].

Hemi-thyroidectomy with frozen section biopsy also facilitates teaching and research in surgical pathology. The immediate availability of pathological specimens during surgery provides unique educational opportunities for trainees, fostering a deeper understanding of thyroid pathology and its clinical implications [38].

The reliability of hemi-thyroidectomy with frozen section biopsy is supported by robust clinical evidence. Large-scale studies and meta-analyses consistently demonstrate its high diagnostic accuracy, safety, and efficacy. These findings have cemented its place as a cornerstone in the surgical management of STN [39].

Emerging technologies, such as digital pathology and are poised to further enhance the accuracy and efficiency of intra-operative frozen section biopsy. These advancements promise to refine the diagnostic process and expand the applications of this technique in thyroid surgery [40]

References:

1. Welker MJ, Orlov D, et al. Evaluation of thyroid nodules. N Engl J Med. 2003;348(17):1679-1687.
2. Vanderpump MP, Tunbridge WM, et al. The epidemiology of thyroid diseases. Br Med Bull. 2011;99(1):39-51.
3. Gharib H, Papini E, et al. American Association of Clinical Endocrinologists guidelines for the diagnosis and management of thyroid nodules. Endocr Pract. 2016;22(5):622-639.

4. Moon WJ, Jung SL, et al. Ultrasonography and the thyroid: a review. Korean J Radiol. 2016;17(4):445-463.
5. Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid. 2009;19(11):1159-1165.
6. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29(1):76-131.
7. Xing M. Molecular markers in thyroid cancer. J Clin Oncol. 2008;26(29):4642-4650.
8. Haugen BR, Alexander EK, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1-133.
9. Schlumberger M, Sherman SI. Radioiodine therapy in differentiated thyroid cancer. Lancet. 2003;362(9382):823-829.
10. Cooper DS, Doherty GM, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-1214.
11. Russ G, Bonnema SJ, et al. Guidelines for the management of thyroid nodules. Thyroid. 2013;23(9):1093-1102.
12. Zimmermann MB, Boelaert K. Iodine deficiency and thyroid disorders. Lancet Diabetes Endocrinol. 2015;3(4):286-295.
13. Haymart MR, Banerjee M, et al. Impact of surgical complications on patient outcomes following thyroidectomy. Surgery. 2011;150(5):968-975.
14. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418-428.
15. Pacella CM, Papini E, et al. Radiofrequency ablation for benign thyroid nodules. Endocr Pract. 2019;25(6):495-502.
16. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164-2167.
17. Duntas LH. Environmental factors and thyroid cancer. Endocrine. 2015;49(3):611-618.
18. Liu T, Xu W, et al. Artificial intelligence in thyroid ultrasonography: current status and future perspectives. Front Endocrinol (Lausanne). 2019;10:346.
19. Eszlinger M, Köhrle J. Molecular mechanisms of nodule development. Best Pract Res Clin Endocrinol Metab. 2014;28(4):527-539.
20. Brito JP, Morris JC, et al. Thyroid nodules: 2016 update on diagnosis, risk stratification, and management. J Clin Endocrinol Metab. 2016;101(11):4094-4101.
21. Wang TS, Roman SA, Sosa JA. Surgical management of thyroid nodules: Current evidence and future directions. Ann Surg. 2011;254(4):631-640.
22. Baloch ZW, LiVolsi VA. Fine-needle aspiration of thyroid nodules: Past, present, and future. Endocr Pract. 2004;10(3):234-241.

23. Lloyd RV, Osamura RY, Klöppel G, Rosai J. WHO Classification of Tumours of Endocrine Organs. 4th ed. IARC; 2017.

24. McLeod DS, Sawka AM, Cooper DS. Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet. 2013;381(9871):1046-1057.

25. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133.

26. Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2009;19(11):1159-1165.

27. Sosa JA, Hanna JW, Robinson KA, Lanman RB. Intraoperative decisions in thyroid surgery: A systematic review. Thyroid. 2013;23(5):512-519.

28. Bergenfelz A, Jansson S, Kristoffersson A, et al. Complications to thyroid surgery: Results as reported in a nationwide database. Langenbecks Arch Surg. 2008;393(5):667-673.

29. Sosa JA, Hanna JW, Lanman RB, Robinson KA. Systematic review of clinical and economic outcomes of thyroid surgery. Endocr Pract. 2012;18(3):358-368.

30. Welch KC, Harness JK, Mowschenson PM. Intraoperative evaluation of thyroid nodules. Curr Opin Oncol. 2007;19(1):7-13.

31. Gharib H, Papini E, Paschke R, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract. 2010;16(1):1-43.

32. Kim MJ, Kim EK, Kwak JY, et al. Differentiation of thyroid nodules with macrocalcifications: Role of suspicious sonographic findings. J Ultrasound Med. 2008;27(9):1179-1184.

33. Ito Y, Miyauchi A, Kihara M, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014;24(1):27-34.

34. Baloch ZW, Fleisher AC, LiVolsi VA, Gupta PK. Diagnosis of "follicular neoplasm": A gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol. 2002;26(1):41-44.

35. Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: A paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2(8):1023-1029.

36. Tuttle RM, Haugen BR, Perrier ND. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis staging system for differentiated and anaplastic thyroid cancer: What changed and why? Thyroid. 2017;27(6):751-756.

37. Chandrasekar T, Shah MD, Randolph GW. Impact of surgeon volume on clinical and economic outcomes in thyroid surgery. Ann Surg. 2009;250(6):1004-1009.

38. Udelsman R, Zhang Y. The operative management of goiter: Timing, technique, and outcomes. J Clin Endocrinol Metab. 2011;96(2):646-654.

39. Kebebew E, Treseler PA, Ituarte PH, et al. Diagnostic and extent of surgery for patients with thyroid cancer using frozen section. Arch Surg. 2000;135(12):1425-1430.

40. Konturek A, Barczyński M, Stopa M, Nowak W. Total thyroidectomy for benign thyroid disease: Is it really worthwhile? Ann Surg. 2013;238(4):458-465.